On Wednesday, in the course of current trade, Shares of JPMorgan Chase & Co. (NYSE:JPM), climbed 0.44%, and is now trading at $68.78.
The 100,000 Jobs Mission declared that its coalition of private companies has grown to over 200 member companies that have collectively hired more than 267,522 U.S. military Veterans through June.
“We are excited that so many well respected businesses have joined us on this mission to collectively hire 300,000 Veterans,” said Ross Brown, director of Military and Veterans Affairs for JPMorgan Chase, a founding member of the coalition. “Our fellow coalition members represent both the best of their business sectors and a commitment to hiring Veterans and their spouses.” The 100,000 Jobs Mission was founded in 2011 by 11 companies counting JPMorgan Chase & Co. that pledged to hire at least 100,000 Veterans by 2020. The coalition reports its hiring results quarterly and shares best practices for hiring and retaining Veterans in their organizations. Many of these can be found on jobsmission.com
JPMorgan Chase & Co. provides various financial services worldwide. The company operates through four segments: Consumer & Community Banking, Corporate & Investment Bank, Commercial Banking, and Asset Administration.
During an Afternoon trade, Shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), dipped -2.97%, and is now trading at $7.84.
ARIAD Pharmaceuticals, stated financial results for the second quarter of 2015, counting revenue from sales of Iclusig (ponatinib). The Company also offered an update on key corporate initiatives and clinical-trial plans.
“During the second quarter, the Company continued strong commercial execution of Iclusig with double-digit percentage, quarter-over-quarter growth in both the U.S. and European markets. We expect additional commercial launches and positive pricing and reimbursement decisions in several European countries during the remainder of the year,” said Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD.
ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of medicines for cancer patients. The company offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, Europe, and other territories.
Finally, Actuant Corporation (NYSE:ATU), gained 0.71% Wednesday.
Actuant Corporation, declared that its Board of Directors has approved a cash dividend on the Company’s common stock. The Board declared an annual dividend of $0.04 per common share payable on October 15, 2015 to shareholders of record at the close of business on September 30, 2015.
Actuant Corporation designs, manufactures, and distributes a range of industrial products and systems worldwide. It operates in three segments: Industrial, Energy, and Engineered Solutions.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
